Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Allied Biotech Corporation (1780:TWSE), powered by AI.
Allied Biotech Corporation is currently trading at $29.80. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Allied Biotech Corporation on Alpha Lenz.
View Allied Biotech Corporation's valuation metrics on Alpha Lenz.
“Allied Biotech Corporation's ROE is 10.7%. Explore profitability and growth together.”
Ask for details →Allied Biotech Corporation is a biotechnology company specializing in the research, development, and production of carotenoid compounds. Founded in 2001 and headquartered in Taipei, the company is recognized as one of the world's leading manufacturers of carotenoids, ranking third globally and first in Asia for a comprehensive product range that includes beta-carotene, canthaxanthin, lycopene, lutein, and related derivatives. Its products serve critical functions as natural colorants and nutritional ingredients in the food, beverage, dietary supplement, and animal feed industries. Notably, Allied Biotech has secured multiple patents in both the United States and European Union for its proprietary production technologies, underscoring its commitment to innovation. In addition to carotenoids, the company manufactures precision chemical materials and other nutraceuticals, supporting sectors such as healthcare, veterinary medicine, and cosmetics. Allied Biotech's global distribution network extends across Asia, Europe, and the Americas, positioning it as a significant player in the international market for specialty food and wellbeing products. Its reputation is further supported by industry awards and recognition for technological advancement and revenue growth.
“Allied Biotech Corporation's ROE is 10.7%. Explore profitability and growth together.”
Ask for details →Allied Biotech Corporation (ticker: 1780) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
The current price is 29.8 with a P/E ratio of -x and P/B of -x.
ROE is 10.65% and operating margin is 14.17%. Annual revenue is $850M.